Author

Chin-I Pai

Observed names: Chin I. Pai, Chin-I. Pai

Institution: Sorrento Therapeutics (United States)

Observed institutions: Sorrento Therapeutics (United States), Institute of Molecular Biology, Academia Sinica, Academia Sinica

ORCID: 0000-0002-2517-6155

Observed ORCID: 0000-0002-2517-6155

OpenAlex ID: A5028613478

Functions of the Upstream and Proximal Steroidogenic Factor 1 (SF-1)-Binding Sites in the CYP11A1 Promoter in Basal Transcription and Hormonal Response

2001 · Meng-Chun Hu, Nai-Chi Hsu, et al. · Molecular Endocrinology · 113

Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants

2022 · J. Andrew Duty, Thomas Kraus, et al. · Med · 21

SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement

2021 · Ying-Ting Wang, Robert D. Allen, et al. · Antiviral Research · 12

Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies

2022 · Xia Cao, Junki Maruyama, et al. · Scientific Reports · 8

Discovery and Development of Human SARS-CoV-2 Neutralizing Antibodies using an Unbiased Phage Display Library Approach

2020 · Xia Cao, Junki Maruyama, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 5

Development of CD19 CAR Engineered Human Placental CD34 +-Derived Natural Killer Cells (CAR19-CYNK) As an Allogeneic Cancer Immunotherapy

2021 · Marina Gergues, Irene Raitman, et al. · Blood · 1

Works count: 6

Citation count: 160

H-index: 5

I10-index: 3